Data Show Survival Improvement In Heart Failure Patients With Reduced Ejection

(RTTNews) - St. Jude Medical Inc (STJ) on Sunday announced a new data analysis from the CHAMPION trial showing that heart failure (HF) patients with reduced ejection fraction on optimal doses of guideline directed medical therapy (GDMT) managed by pulmonary artery (PA) pressure monitoring with the CardioMEMS HF System had a 57 percent reduction in mortality and a 43 percent reduction in HF hospitalizations compared with patients on GDMT managed by the standard of care (SOC).

According to the medical device company, these data show a strong improvement for patients managed by optimal GDMT and the CardioMEMS HF System in both mortality and hospitalizations over currently defined best practices.

The analysis looked at patients with HF and reduced ejection fraction (HFrEF) (when the heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body) over an average of 17 months who were on optimal GDMT and compared those managed by PA pressure monitoring with the CardioMEMS HF System to those managed by SOC. The CHAMPION trial retrospective analysis demonstrated that PA pressure monitoring, in addition to GDMT, significantly reduced HF hospitalizations and mortality in patients with reduced ejection fraction.